-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $91

Benzinga·11/13/2026 17:56:02
Diffusion vocale
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $88 to $91.